Biobetter Bo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biobetter bo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biobetter Bo Today - Breaking & Trending Today

CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) .
CytoDel IncJanuary 7, 2021 GMT
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection
Supports the Development of New Approaches to Treat Multiple Neurological Diseases
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) CytoDel, Inc. (“CytoDel” or “the Company”), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto-111, in the peer-reviewed journal,
Science Translational Medicine. The complete text of the article titled, “Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,” can be found here. ....

Biobetter Bo , Konstantin Ichtchenko , School Of Medicine , Langone Health , Research Professor , National Institute Of Health , National Institute Of Allergy , Department Of Biochemistry , Cytodel Inc , Grossman School Of Medicine , Department Of Molecular , Behavioral Sciences At Stanford University , Howard Hughes Medical Institute , Studies Show , Previously Inaccessible Intraneuronal Targets , Viral Vector , New Approaches , Treat Multiple Neurological , Science Translational , Therapeutic Effects , Animal Models , Molecular Pharmacology , National Institute , Infectious Diseases , Cellular Physiology , Behavioral Sciences ,

CytoDel announces successful intra-neuronal antibody delivery without a viral vector


 E-Mail
New York City, January 6, 2021 - CytoDel, Inc. ( CytoDel or the Company ), a privately-held corporation, today announces the publication of preclinical data on the Company s lead product, Cyto-111, in the peer-reviewed journal,
Science Translational Medicine. The complete text of the article titled, Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism, can be found here.
Cyto-111 was conceived, expressed and purified in the laboratory of Konstantin Ichtchenko, Ph.D., NYU Grossman School of Medicine, Department of Biochemistry and Molecular Pharmacology, who was a principal investigator in the study, which was supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institute of Health (NIH). ....

New York , United States , Biobetter Bo , Konstantin Ichtchenko , School Of Medicine , Langone Health , Research Professor , National Institute Of Health , National Institute Of Allergy , Department Of Biochemistry , Cytodel Inc , Tufts University Center , Grossman School Of Medicine , Department Of Molecular , Behavioral Sciences At Stanford University , Howard Hughes Medical Institute , New York City , Science Translational , Therapeutic Effects , Animal Models , Molecular Pharmacology , National Institute , Infectious Diseases , Cellular Physiology , Behavioral Sciences , Stanford University ,